PPAR gamma: Coordinating metabolic and immune contributions to female fertility

PPAR Research

Volumn , Issue , 2008, Pages

  Minge, Cadence E ^a   Robker, Rebecca L ^a   Norman, Robert J ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; CD36 ANTIGEN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; SCAVENGER RECEPTOR BI;

BONE DISEASE; CELL FUNCTION; CHRONIC INFLAMMATION; DRUG EFFECT; FEMALE FERTILITY; FLUID RETENTION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE STRUCTURE; HUMAN; INSULIN SENSITIVITY; LIPID TRANSPORT; MACROPHAGE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; PHENOTYPE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 38649087619     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/243791     Document Type: Review

References (207)

1. C. M. Komar ckomar@iastate.edu T. E. Curry Jr. Inverse relationship between the expression of messenger ribonucleic acid for peroxisomeproliferator- activated receptor γ and P450 side chain cleavage in the rat ovary. Biology of Reproduction 69 2 2003 549 555
2. C. E. Minge N. K. Ryan K. H. Van Der Hoek R. L. Robker R. J. Norman robert.norman@adelaide.edu.au Troglitazone regulates peroxisome proliferator-activated receptors and inducible nitric oxidesynthase in murine ovarian macrophages. Biology of Reproduction 74 1 2006 153 160
3. C. M. Komar ckomar@uky.edu O. Braissant W. Wahli T. E. Curry Jr. Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 142 11 2001 4831 4838
4. S. Gasic Y. Bodenburg M. Nagamani A. Green R. J. Urban rurban@utmb.edu Troglitazone inhibits progesterone production in porcine granulosa cells. Endocrinology 139 12 1998 4962 4966
5. M. Mohan J. R. Malayer R. D. Geisert G. L. Morgan Expression patterns of retinoid X receptors, retinaldehyde dehydrogenase, and peroxisome proliferatoractivated receptor γ in bovine preattachment embryos. Biology of Reproduction 66 3 2002 692 700
6. P. Froment S. Fabre J. Dupont Expression and functional role of peroxisome proliferator-activated receptor-γ in ovarian folliculogenesis in the sheep. Biology of Reproduction 69 5 2003 1665 1674
7. C. Dreyer dreyer@gen.mpibtuebingen.mpg.de H. Ellinger-Ziegelbauer Retinoic acid receptors and nuclear orphan receptors in the development of Xenopus laevis. International Journal of Developmental Biology 40 1 1996 255 262
8. C. M. Komar T. E. Curry Jr. Localization and expression of messenger RNAs for the peroxisome proliferator-activatedreceptors in ovarian tissue from naturally cycling and pseudopregnant rats. Biology of Reproduction 66 5 2002 1531 1539
9. C. M. Komar ckomar@iastate.edu Peroxisome proliferator-activated receptors (PPARs) and ovarian function - implications forregulating steroidogenesis, differentiation, and tissue remodeling. Reproductive Biology and Endocrinology 3 41 2005
10. P. Froment froment@lyon.inserm.fr F. Gizard D. Defever B. Staels J. Dupont P. Monget Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. Journal of Endocrinology 189 2 2006 199 209
11. R. Wu K. H. Van der Hoek N. K. Ryan R. J. Norman R. L. Robker Rebecca.robker@adelaide.edu.au Macrophage contributions to ovarian function. Human Reproduction Update 10 2 2004 119 133
12. O. Braissant F. Foufelle C. Scotto M. Dauça W. Wahli Differential expression of peroxisome proliferator-activated receptors (PPARs):tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137 1 1996 354 366
13. Y. Cui Yongzhic@intra.niddk.nih.gov K. Miyoshi E. Claudio Loss of the peroxisome proliferation-activated receptor γ (PPARγ) does not affectmammary development and propensity for tumor formation but leads to reduced fertility. Journal of Biological Chemistry 277 20 2002 17830 17835
14. P. D. Schoppee J. C. Garmey J. D. Veldhuis Putative activation of the peroxisome proliferator-activated receptor γ impairs androgen and enhancesprogesterone biosynthesis in primary cultures of porcine theca cells. Biology of Reproduction 66 1 2002 190 198
15. B. Löhrke T. Viergutz S. K. Shahi Detection and functional characterisation of the transcription factor peroxisomeproliferator-activated receptor γ in lutein cells. Journal of Endocrinology 159 3 1998 429 439
16. H. Sundvold A. Brzozowska S. Lien Characterisation of bovine peroxisome proliferator-activated receptors γ1 and γ2:genetic mapping and differential expression of the two isoforms. Biochemical and Biophysical Research Communications 239 3 1997 857 861
17. K. G. Lambe J. D. Tugwood A human peroxisome-proliferator-activated receptor-γ is activated by inducers of adipogenesis,including thiazalidinedione drugs. European Journal of Biochemistry 239 1 1996 1 7
18. Y.-M. Mu T. Yanase yanase@mail.server.med.kyushu-u.ac.jp Y. Nishi Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochemical and Biophysical Research Communications 271 3 2000 710 713
19. A. Chawla E. J. Schwarz D. D. Dimaculangan M. A. Lazar Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early inadipocyte differentiation. Endocrinology 135 2 1994 798 800
20. A. Chawla Y. Barak L. Nagy D. Liao P. Tontonoz R. M. Evans PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nature Medicine 7 1 2001 48 52
21. P. Tontonoz E. Hu B. M. Spiegelman Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79 7 1994 1147 1156
22. E. D. Rosen P. Sarraf A. E. Troy PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Molecular Cell 4 4 1999 611 617
23. Y. Barak M. C. Nelson E. S. Ong PPARγ is required for placental, cardiac, and adipose tissue development. Molecular Cell 4 4 1999 585 595
24. M. J. Davies michael.davies@adelaide.edu.au Evidence for effects of weight on reproduction in women. Reproductive BioMedicine Online 12 5 2006 552 561
25. R. J. Norman rnorman@medicine.adelaide.edu.au A. M. Clark Obesity and reproductive disorders: a review. Reproduction, Fertility and Development 10 1 1998 55 63
26. Y.-M. Mu T. Yanase yanase@mail.server.med.kyushu-u.ac.jp Y. Nishi Saturated FFAs, palmitic acid and stearic acid, induce apoptosis in human granulosa cells. Endocrinology 142 8 2001 3590 3597
27. R. Jorritsma r.jorritsma@vet.uu.nl M. L. César J. T. Hermans C. L. J. J. Kruitwagen P. L. A. M. Vos T. A. M. Kruip Effects of non-esterified fatty acids on bovine granulosa cells and developmental potential of oocytes in vitro. Animal Reproduction Science 81 3-4 2004 225 235
28. T. Vanholder Tom.Vanholder@UGent.be J. L. M. R. Leroy A. Van Soom Effect of non-esterified fatty acids on bovine granulosa cell steroidogenesis and proliferation in vitro. Animal Reproduction Science 87 1-2 2005 33 44
29. M. Mitchell D. T. Armstrong R. L. Robker R. J. Norman di.sutton@adelaide.edu.au Adipokines: implications for female fertility and obesity. Reproduction 130 5 2005 583 597
30. A. M. Bodles V. Varma A. Yao-Borengasser Pioglitazone induces apoptosis of macrophages in human adipose tissue. Journal of Lipid Research 47 9 2006 2080 2088
31. L. Fajas J.-C. Fruchart J. Auwerx johan.auwerx@pasteur-lille.fr PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Letters 438 1-2 1998 55 60
32. P. Tontonoz R. A. Graves A. I. Budavari Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclearhormone receptors, PPAR γ and RXR α Nucleic Acids Research 22 25 1994 5628 5634
33. H. Sundvold S. Lien Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in manand transactivation by the nuclear receptor RORα1. Biochemical and Biophysical Research Communications 287 2 2001 383 390
34. B. Desvergne W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20 5 1999 649 688
35. R. Mukherjee rmukherjee@ligand.com L. Jow G. E. Croston J. R. Paterniti Jr. Identification, characterization, and tissue distribution of human peroxisomeproliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation withretinoid X receptor agonists and antagonists. Journal of Biological Chemistry 272 12 1997 8071 8076
36. L. Fajas D. Auboeuf E. Raspé The organization, promoter analysis, and expression of the human PPARγ gene. Journal of Biological Chemistry 272 30 1997 18779 18789
37. T. E. Akiyama S. Sakai G. Lambert Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results inlowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Molecular and Cellular Biology 22 8 2002 2607 2619
38. H. Koutnikova T.-A. Cock M. Watanabe Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ hypomorphic mice. Proceedings of the National Academy of Sciences of the United States of America 100 24 2003 14457 14462
39. D. Altshuler J. N. Hirschhorn M. Klannemark The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nature Genetics 26 1 2000 76 80
40. S. S. Deeb deeb@genetics.washington.edu L. Fajas M. Nemoto A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body massindex and improved insulin sensitivity. Nature Genetics 20 3 1998 284 287
41. M. M. Swarbrick C. M. L. Chapman B. M. McQuillan J. Hung P. L. Thompson J. P. Beilby A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-γ2 is associated withcombined hyperlipidaemia in obesity. European Journal of Endocrinology 144 3 2001 277 282
42. B. A. Beamer C.-J. Yen R. E. Andersen Association of the Pro12Ala variant in the peroxisome proliferator- activated receptor-γ2 gene with obesityin two Caucasian populations. Diabetes 47 11 1998 1806 1808
43. E. C. Tok A. Aktas D. Ertunc devrimertunc@hotmail.com E. M. Erdal S. Dilek Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basisof peroxisome proliferator-activated receptor (PPAR)-γ2 Pro12Ala genotype. Human Reproduction 20 6 2005 1590 1595
44. A. Meirhaeghe L. Fajas N. Helbecque A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Human Molecular Genetics 7 3 1998 435 440
45. F. Orio Jr. f.orio@tin.it G. Matarese S. Di Biase Exon 6 and 2 peroxisome proliferator-activated receptor-γ polymorphisms in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 88 12 2003 5887 5892
46. A. Doney B. Fischer D. Frew Haplotype analysis of the PPARγ Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genetics 3 1 2002 21
47. J. Ek G. Andersen S. A. Urhammer Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 (PPAR-γ2) genein relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 44 9 2001 1170 1176
48. C. Vigouroux L. Fajas E. Khallouf Human peroxisome proliferator-activated receptor-γ2: genetic mapping, identification of a variant in thecoding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes 47 3 1998 490 492
49. J. Pihlajamäki R. Miettinen R. Valve The Pro12Ala substitution in the peroxisome proliferator activated receptor γ 2 is associated with aninsulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 151 2 2000 567 574
50. A. Hamann H. Münzberg P. Buttron Missense variants in the human peroxisome proliferator-activated receptor-γ2 gene in lean and obese subjects. European Journal of Endocrinology 141 1 1999 90 92
51. J. Ringel S. Engeli A. Distler A. M. Sharma sharma@zedat.fu-berlin.de Pro12Ala missense mutation of the peroxisome proliferator activated receptor γ and diabetes mellitus. Biochemical and Biophysical Research Communications 254 2 1999 450 453
52. Y. Mori H. Kim-Motoyama T. Katakura Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor γ2 gene onadiposity, fat distribution, and insulin sensitivity in Japanese men. Biochemical and Biophysical Research Communications 251 1 1998 195 198
53. M. Koch K. Rett E. Maerker The PPARγ2 amino acid polymorphism Pro12Ala is prevalent in offspring of type II diabetic patients and isassociated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia 42 6 1999 758 762
54. K. Hara T. Okada K. Tobe The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochemical and Biophysical Research Communications 271 1 2000 212 216
55. M. Yilmaz murartt@hotmail.com M. Ali Ergün A. Karakoç E. Yurtçu N. Çakir M. Arslan Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome. Gynecological Endocrinology 22 6 2006 336 342
56. S. Hahn A. Fingerhut U. Khomtsiv The peroxisome proliferator activated receptor γ Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome. Clinical Endocrinology 62 5 2005 573 579
57. S. Korhonen S. Heinonen seppo.heinonen@kuh.fi M. Hiltunen Polymorphism in the peroxisome proliferator-activated receptor-γ gene in women with polycystic ovary syndrome. Human Reproduction 18 3 2003 540 543
58. M. Ristow D. Müller-Wieland A. Pfeiffer W. Krone C. R. Kahn Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New England Journal of Medicine 339 14 1998 953 959
59. I. Barroso M. Gurnell V. E. F. Crowley Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitusand hypertension. Nature 402 6764 1999 880 883
60. D. B. Savage G. D. Tan C. L. Acerini Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptorperoxisome proliferator-activated receptor-γ Diabetes 52 4 2003 910 917
61. R. A. Hegele hegele@robarts.ca H. Cao C. Frankowski S. T. Mathews T. Leff PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. Diabetes 51 12 2002 3586 3590
62. A. K. Agarwal A. Garg A novel heterozygous mutation in peroxisome proliferator-activated receptor-γ gene in a patient withfamilial partial lipodystrophy. Journal of Clinical Endocrinology and Metabolism 87 1 2002 408 411
63. H. E. Xu M. H. Lambert V. G. Montana Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proceedings of the National Academy of Sciences of the United States of America 98 24 2001 13919 13924
64. J. Berger D. E. Moller The mechanisms of action of PPARs. Annual Review of Medicine 53 2002 409 435
65. A. Tsafriri Ovulation as a tissue remodelling process: proteolysis and cumulus expansion. Advances in Experimental Medicine and Biology 377 1995 121 140
66. B. Dennefors L. Hamberger T. Hillensjo Aspects concerning the role of prostaglandins for ovarian function. Acta Obstetricia et Gynecologica Scandinavica 113, supplement 1983 31 41
67. G. Evans M. Dobias G. J. King D. T. Armstrong Production of prostaglandins by porcine preovulatory follicular tissues and their roles in intrafollicular function. Biology of Reproduction 28 2 1983 322 328
68. D. T. Armstrong Prostaglandins and follicular functions. Journal of Reproduction and Fertility 62 1 1981 283 291
69. A. V. Pontsler A. St Hilaire G. K. Marathe G. A. Zimmerman T. M. McIntyre tom.mcintyre@hmbg.utah.edu Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor γ and oxidizedalkyl phospholipids from oxidized low density lipoprotein. Journal of Biological Chemistry 277 15 2002 13029 13036
70. M. F. M. Mitwally N. K. Kuscu T. M. Yalcinkaya High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Human Reproduction 14 11 1999 2700 2703
71. I. Hasegawa H. Murakawa M. Suzuki Y. Yamamoto T. Kurabayashi K. Tanaka Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertility and Sterility 71 2 1999 323 327
72. D. A. Ehrmann dehrmann@medicine.bsd.uchicago.edu D. J. Schneider B. E. Sobel Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 82 7 1997 2108 2116
73. R. Azziz D. Ehrmann R. S. Legro Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 86 4 2001 1626 1632
74. F. Picard J. Auwerx PPARγ and glucose homeostasis. Annual Review of Nutrition 22 2002 167 197
75. A. A. Rouzi aarouzi@hotmail.com M. S. M. Ardawi A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. Fertility and Sterility 85 2 2006 428 435
76. C. Ortega-González ortegacarlos@.hotmail.com S. Luna L. Hernández Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 90 3 2005 1360 1365
77. N. Brettenthaler C. De Geyter cdegeyter@uhbs.ch P. R. Huber U. Keller Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 89 8 2004 3835 3840
78. S. H. Belli M. N. Graffigna A. Oneto P. Otero L. Schurman O. A. Levalle levalle@pure.com.ar Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome. Fertility and Sterility 81 3 2004 624 629
79. A. Shobokshi M. Shaarawy Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. Journal of the Society for Gynecologic Investigation 10 2 2003 99 104
80. D. Seto-Young dyoung@chpnet.org M. Paliou J. Schlosser Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. Journal of Clinical Endocrinology and Metabolism 90 11 2005 6099 6105
81. S. Gasic M. Nagamani A. Green R. J. Urban Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary. American Journal of Obstetrics and Gynecology 184 4 2001 575 579
82. M. S. Coffler K. Patel M. H. Dahan R. Y. Yoo P. J. Malcom R. J. Chang rjchang@ucsd.edu Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone. Journal of Clinical Endocrinology and Metabolism 88 12 2003 5624 5631
83. C. E. Minge B. D. Bennett M. Lane R. J. Norman R. L. Robker Obesity-induced female infertility arises from impaired oocyte developmental competence and can be reversed by peri-ovulatory rosiglitazone treatment. Proceedings of the 10th International Congress on Obesity Sydney, Australia 2006
84. W. L. Miller wlmlab@ucsf.edu Steroidogenic acute regulatory protein (StAR), a novel mitochondrial cholesterol transporter. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1771 6 2007 663 676
85. D. Seto-Young dyoung@chpnet.org D. Avtanski M. Strizhevsky Interactions among peroxisome proliferator activated receptor-γ, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. Journal of Clinical Endocrinology and Metabolism 92 6 2007 2232 2239
86. W. C. Duncan G. M. Cowen P. J. Illingworth Steroidogenic enzyme expression in human corpora lutea in the presence and absence of exogenous human chorionic gonadotrophin (HCG). Molecular Human Reproduction 5 4 1999 291 298
87. K. J. Doody M. C. Lorence J. I. Mason E. R. Simpson Expression of messenger ribonucleic acid species encoding steroidogenic enzymes in human follicles and corpora lutea throughout the menstrual cycle. Journal of Clinical Endocrinology and Metabolism 70 4 1990 1041 1045
88. W. Arlt R. J. Auchus W. L. Miller wlmlab@itsa.ucsf.edu Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3β-hydroxysteroid dehydrogenase. Journal of Biological Chemistry 276 20 2001 16767 16771
89. P. Kempná G. Hofer P. E. Mullis C. E. Flück christa.flueck@insel.ch Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Molecular Pharmacology 71 3 2007 787 798
90. J. D. Veldhuis jdv@virginia.edu G. Zhang J. C. Garmey Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro. Journal of Clinical Endocrinology and Metabolism 87 3 2002 1129 1133
91. M. P. Steinkampf C. R. Mendelson E. R. Simpson Regulation by follicle-stimulating hormone of the synthesis of aromatase cytochrome P-450 in human granulosa cells. Molecular Endocrinology 1 7 1987 465 471
92. J. S. Krasnow G. J. Hickey J. S. Richards Regulation of aromatase mRNA and estradiol biosynthesis in rat ovarian granulosa and luteal cells by prolactin. Molecular Endocrinology 4 1 1990 13 21
93. T. Yanase yanase@intemed3.med.kyushu-u.ac.jp Y.-M. Mu Y. Nishi Regulation of aromatase by nuclear receptors. Journal of Steroid Biochemistry and Molecular Biology 79 1-5 2001 187 192
94. Y.-M. Mu T. Yanase yanase@mail.server.med.kyushu-u.ac.jp Y. Nishi R. Takayanagi K. Goto H. Nawata Combined treatment with specific ligands for PPARγ:RXR nuclear receptor system markedly inhibits the expression of cytochrome P450arom in human granulosa cancer cells. Molecular and Cellular Endocrinology 181 1-2 2001 239 248
95. W. Fan T. Yanase yanase@intmed3.med.kyushu-u.ac.jp H. Morinaga Activation of peroxisome proliferator-activated receptor-γ and retinoid X receptor inhibits aromatase transcription via nuclear factor-κB. Endocrinology 146 1 2005 85 92
96. K. Rautio J. S. Tapanainen juha.tapanainen@oulu.fi A. Ruokonen L. C. Morin-Papunen Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Human Reproduction 21 6 2006 1400 1407
97. H. M. Garmes heraldmg@uol.com.br M. A. Tambascia D. E. Zantut-Wittmann Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome. Gynecological Endocrinology 21 6 2005 317 323
98. M. Yilmaz murartt@hotmail.com A. Biri A. Karakoç The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. Journal of Endocrinological Investigation 28 11 2005 1003 1008
99. M. Yilmaz murartt@hotmail.com N. Bukan G. Ayvaz The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Human Reproduction 20 12 2005 3333 3340
100. M. Yilmaz murartt@hotmail.com A. Karakoç F. B. Törüner The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. Gynecological Endocrinology 21 3 2005 154 160
101. D. Dereli T. Dereli F. Bayraktar A. G. Ozgen C. Yilmaz Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocrine Journal 52 3 2005 299 308
102. V. Sepilian M. Nagamani mnagaman@utmb.edu Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. Journal of Clinical Endocrinology and Metabolism 90 1 2005 60 65
103. J.-P. Baillargeon D. J. Jakubowicz M. J. Iuorno S. Jakubowicz J. E. Nestler nestler@hsc.vcu.edu Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertility and Sterility 82 4 2004 893 902
104. D. Romualdi M. Guido M. Ciampelli Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. Human Reproduction 18 6 2003 1210 1218
105. T. Lovekamp-Swan A. M. Jetten B. J. Davis davis1@niehs.nih.gov Dual activation of PPARα and PPARγ by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells. Molecular and Cellular Endocrinology 201 1-2 2003 133 141
106. A. Rubenstrunk R. Hanf D. W. Hum J.-C. Fruchart B. Staels Bart.Staels@pasteur-lille.fr Safety issues and prospects for future generations of PPAR modulators. Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids 1771 8 2007 1065 1081
107. A. V. Schwartz aschwartz@psg.ucsf.edu D. E. Sellmeyer E. Vittinghoff Thiazolidinedione use and bone loss in older diabetic adults. Journal of Clinical Endocrinology and Metabolism 91 9 2006 3349 3354
108. D. B. Klinkner H. J. Lim E. Y. Strawn Jr. K. T. Oldham T. L. Sander sandert@mcw.edu An in vivo murine model of rosiglitazone use in pregnancy. Fertility and Sterility 86 4 2006 1074 1079
109. N. A. Cataldo ncataldo@Stanford.edu F. Abbasi T. L. McLaughlin C. Lamendola G. M. Reaven Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fertility and Sterility 76 5 2001 1057 1059
110. L. Y.-S. Chan lyschan@cuhk.edu.hk J. H.-K. Yeung T. K. Lau Placental transfer of rosiglitazone in the first trimester of human pregnancy. Fertility and Sterility 83 4 2005 955 958
111. A. Dunaif Insulin action in the polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America 28 2 1999 341 359
112. L. Poretsky J. Clemons K. Bogovich Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism 41 8 1992 903 910
113. N. K. Kuşcu F. Koyuncu K. Özbilgin S. Inan I. Tuǧlu Ö. Karaer Insulin: does it induce follicular arrest in the rat ovary? Gynecological Endocrinology 16 5 2002 361 364
114. S. Hashimoto N. Minami M. Yamada H. Imai Excessive concentration of glucose during in vitro maturation impairs the developmental competence of bovine oocytes after in vitro fertilization: relevance to intracellular reactive oxygen species and glutathione contents. Molecular Reproduction and Development 56 4 2000 520 526
115. S. A. Colton G. M. Pieper S. M. Downs Altered meiotic regulation in oocytes from diabetic mice. Biology of Reproduction 67 1 2002 220 231
116. J. Rieusset J. Auwerx H. Vidal vidal@laennec.univ-lyon1.fr Regulation of gene expression by activation of the peroxisome proliferator-activated receptor γ with rosiglitazone (BRL 49653) in human adipocytes. Biochemical and Biophysical Research Communications 265 1 1999 265 271
117. U. Smith S. Gogg A. Johansson T. Olausson V. Rotter B. Svalstedt Thiazolidinediones (PPARγ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB Journal 15 1 2001 215 220
118. T. P. Ciaraldi A. P. S. Kong N. V. Chu Regulation of glucose transport and insulin signaling by troglitazone or metformin in adipose tissue of type 2 diabetic subjects. Diabetes 51 1 2002 30 36
119. L. M. Furtado V. Poon A. Klip GLUT4 activation: thoughts on possible mechanisms. Acta Physiologica Scandinavica 178 4 2003 287 296
120. N. Khandoudi P. Delerive I. Berrebi-Bertrand R. E. Buckingham B. Staels A. Bril antoine_bril@gsk.com Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 51 5 2002 1507 1514
121. G. Jiang guoqiang.jiang@merck.com Q. Dallas-Yang S. Biswas Z. Li B. B. Zhang Rosiglitazone, an agonist of peroxisome-proliferator-activated receptor γ (PPARγ), decreases inhibitory serine phosphorylation of IRS1 in vitro and in vivo. Biochemical Journal 377 2 2004 339 346
122. G. Jiang B. B. Zhang bei_zhang@merck.com Modulation of insulin signalling by insulin sensitizers. Biochemical Society Transactions 33 2 2005 358 361
123. L. Guo R. Tabrizchi rtabrizc@mun.ca Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacology and Therapeutics 111 1 2006 145 173
124. S.-Y. Ku S. D. Kim B. C. Jee Clinical efficacy of body mass index as predictor of in vitro fertilization and embryo transfer outcomes. Journal of Korean Medical Science 21 2 2006 300 303
125. A. Bongain bongain@mail.azur.fr V. Isnard J.-Y. Gillet Obesity in obstetrics and gynaecology. European Journal of Obstetrics Gynecology and Reproductive Biology 77 2 1998 217 228
126. Y. Linné Yvonne.Linne@medhs.ki.se Effects of obesity on women's reproduction and complications during pregnancy. Obesity Reviews 5 3 2004 137 143
127. G. A. Bray Obesity and reproduction. Human Reproduction 12 1 1997 26 32
128. J. X. Wang M. Davies R. J. Norman Body mass and probability of pregnancy during assisted reproduction treatment: retrospective study. British Medical Journal 321 7272 2000 1320 1321
129. R. Pasquali rpasqual@almadns.unibo.it C. Pelusi S. Genghini M. Cacciari A. Gambineri Obesity and reproductive disorders in women. Human Reproduction Update 9 4 2003 359 372
130. B. M. Zaadstra J. C. Seidell P. A. H. Van Noord Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. British Medical Journal 306 6876 1993 484 487
131. A. Fukuhara M. Matsuda M. Nishizawa Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 5708 2005 426 430
132. T. E. Graham Q. Yang M. Blüher Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New England Journal of Medicine 354 24 2006 2552 2563
133. B. K. Tan J. Chen J. E. Digby S. D. Keay C. R. Kennedy H. S. Randeva hrandeva@bio.warwick.ac.uk Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. Journal of Clinical Endocrinology and Metabolism 91 12 2006 5022 5028
134. B. K. Tan J. Chen H. Lehnert R. Kennedy H. S. Randeva harpal.randeva@warwick.ac.uk Raised serum, adipocyte, and adipose tissue retinol-binding protein 4 in overweight women with polycystic ovary syndrome: effects of gonadal and adrenal steroids. Journal of Clinical Endocrinology and Metabolism 92 7 2007 2764 2772
135. M. Iwaki M. Matsuda N. Maeda Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52 7 2003 1655 1663
136. P. De Vos A.-M. Lefebvre S. G. Miller Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ Journal of Clinical Investigation 98 4 1996 1004 1009
137. D. Sinha S. Addya E. Murer G. Boden 15-Deoxy-Δ12,14 prostaglandin J2: a putative endogenous promoter of adipogenesis suppresses the ob gene. Metabolism 48 6 1999 786 791
138. C. B. Kallen M. A. Lazar Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proceedings of the National Academy of Sciences of the United States of America 93 12 1996 5793 5796
139. Y. Miyazaki A. Mahankali E. Wajcberg M. Bajaj L. J. Mandarino R. A. DeFronzo albarado@uthscsa.edu Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 89 9 2004 4312 4319
140. C. Otto carsten.otto@med.uni-muenchen.de B. Otto B. Göke Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulinresistance as well as ghrelin and resistin levels. Journal of Endocrinological Investigation 29 3 2006 231 236
141. L. J. Spicer C. C. Francisco The adipose obese gene product, leptin: evidence of a direct inhibitory role in ovarian function. Endocrinology 138 8 1997 3374 3379
142. C. Karlsson K. Lindell E. Svensson Expression of functional leptin receptors in the human ovary. Journal of Clinical Endocrinology and Metabolism 82 12 1997 4144 4148
143. N. K. Ryan K. H. Van der Hoek S. A. Robertson R. J. Norman robert.norman@adelaide.edu.au Leptin and leptin receptor expression in the rat ovary. Endocrinology 144 11 2003 5006 5013
144. R. J. Zachow D. A. Magoffin Direct intraovarian effects of leptin: impairment of the synergistic action of insulin-like growthfactor-I on follicle-stimulating hormone- dependent estradiol-17β production by rat ovarian granulosa cells. Endocrinology 138 2 1997 847 850
145. N. K. Ryan C. M. Woodhouse K. H. Van der Hoek R. B. Gilchrist D. T. Armstrong R. J. Norman Expression of leptin and its receptor in the murine ovary: possible role in the regulation of oocyte maturation. Biology of Reproduction 66 5 2002 1548 1554
146. J. E. Swain R. L. Dunn D. McConnell J. Gonzalez-Martinez G. D. Smith smithgd@umich.edu Direct effects of leptin on mouse reproductive function: regulation of follicular, oocyte, and embryo development. Biology of Reproduction 71 5 2004 1446 1452
147. E. Lord S. Ledoux B. D. Murphy D. Beaudry M. F. Palin palinmf@agr.gc.ca Expression of adiponectin and its receptors in swine. Journal of Animal Science 83 3 2005 565 578
148. S. Ledoux D. B. Campos F. L. Lopes M. Dobias-Goff M.-F. Palin B. D. Murphy bruce.d.murphy@umontreal.ca Adiponectin induces periovulatory changes in ovarian follicular cells. Endocrinology 147 11 2006 5178 5186
149. P. Tontonoz E. Hu J. Devine E. G. Beale B. M. Spiegelman PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Molecular and Cellular Biology 15 1 1995 351 357
150. K. Schoonjans J. Peinado-Onsurbe A.-M. Lefebvre PPARα and PPARγ activators direct a distinct tissue-specific transcriptional responsevia a PPRE in the lipoprotein lipase gene. EMBO Journal 15 19 1996 5336 5348
151. S. R. Ross R. A. Graves A. Greenstein A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo. Proceedings of the National Academy of Sciences of the United States of America 87 24 1990 9590 9594
152. M. Watanabe K. Inukai inukai@saitama-med.ac.jp H. Katagiri T. Awata Y. Oka S. Katayama Regulation of PPARγ transcriptional activity in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications 300 2 2003 429 436
153. P. Tontonoz L. Nagy J. G. A. Alvarez V. A. Thomazy R. M. Evans PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 2 1998 241 252
154. G. Chinetti F. G. Gbaguidi S. Griglio CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisomeproliferator-activated receptors. Circulation 101 20 2000 2411 2417
155. J. J. Petrik P. A. Gentry J.-J. Feige J. LaMarre Expression and localization of thrombospondin-1 and -2 and their cell-surface receptor, CD36, duringrat follicular development and formation of the corpus luteum. Biology of Reproduction 67 5 2002 1522 1531
156. J. Greenaway P. A. Gentry J.-J. Feige J. LaMarre J. J. Petrik jpetrik@uoguelph.ca Thrombospondin and vascular endothelial growth factor are cyclically expressedin an inverse pattern during bovine ovarian follicle development. Biology of Reproduction 72 5 2005 1071 1078
157. J. E. Murphy-Ullrich The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? Journal of Clinical Investigation 107 7 2001 785 790
158. S. Goicoechea A. W. Orr M. A. Pallero P. Eggleton J. E. Murphy-Ullrich Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. Journal of Biological Chemistry 275 46 2000 36358 36368
159. L. Nagy P. Tontonoz J. G. A. Alvarez H. Chen R. M. Evans Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ Cell 93 2 1998 229 240
160. M. Ricote J. T. Huang J. S. Welch C. K. Glass cglass@ucsd.edu The peroxisome proliferator-activated receptorγ (PPARγ) as a regulator of monocyte/macrophage function. Journal of Leukocyte Biology 66 5 1999 733 739
161. P.-A. Svensson M. S. C. Johnson C. Ling L. M. S. Carlsson H. Billig B. Carlsson bjorn.carlsson@ss.gu.se Scavenger receptor class B type I in the rat ovary:possible role in high density lipoprotein cholesterol uptake and in the recognition of apoptotic granulosa cells. Endocrinology 140 6 1999 2494 2500
162. E. Reaven eve@icon.palo-alto.med.va.gov A. Nomoto S. Leers-Sucheta R. Temel D. L. Williams S. Azhar Expression and microvillar localization of scavenger receptor, class B, type I (a high density lipoprotein receptor)in luteinized and hormone- desensitized rat ovarian models. Endocrinology 139 6 1998 2847 2856
163. M. Ricote J. Huang L. Fajas Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulationin macrophages by colony stimulating factors and oxidized low density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 95 13 1998 7614 7619
164. M. Ricote A. C. Li T. M. Willson C. J. Kelly C. K. Glass cglass@ucsd.edu The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391 6662 1998 79 82
165. R. B. Clark rclark@nso2.uchc.edu D. Bishop-Bailey T. Estrada-Hernandez T. Hla L. Puddington S. J. Padula The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses. Journal of Immunology 164 3 2000 1364 1371
166. Y. Azuma M. Shinohara P.-L. Wang K. Ohura 15-deoxy-Δ12,14- prostaglandin J 2 inhibits IL-10 and IL-12 production by macrophages. Biochemical and Biophysical Research Communications 283 2 2001 344 346
167. P. Wang ping.wang@wblab.lu.se P. O. Anderson S. Chen K. M. Paulsson H.-O. Sjögren S. Li su-ling.li@wblab.lu.se Inhibition of the transcription factors AP-1 and NF-κB in CD4 T cells by peroxisomeproliferator-activated receptor γ ligands. International Immunopharmacology 1 4 2001 803 812
168. D. G. Alleva dalleva@neurocrine.com E. B. Johnson F. M. Lio S. A. Boehme P. J. Conlon P. D. Crowe pcrowe@neurocrine.com Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands forperoxisome proliferator-activated receptor-γ: counter-regulatory activity by IFN-γ Journal of Leukocyte Biology 71 4 2002 677 685
169. M. Okada S. F. Yan D. J. Pinsky djp5@columbia.edu Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB Journal 16 14 2002 1861 1868
170. B. Hinz hinz@pharmakologie.uni-erlangen.de K. Brune A. Pahl 15-deoxy-Δ12,14-prostaglandin J 2 inhibits the expression of proinflammatory genes inhuman blood monocytes via a PPAR-γ-independent mechanism. Biochemical and Biophysical Research Communications 302 2 2003 415 420
171. K. Asada S. Sasaki T. Suda suda@hama-med.ac.jp K. Chida H. Nakamura Antiinflammatory roles of peroxisome proliferator-activated receptor γ in human alveolar macrophages. American Journal of Respiratory and Critical Care Medicine 169 2 2004 195 200
172. G. Chinetti J.-C. Fruchart B. Staels bart.staels@pasteur-lille.fr Peroxisome proliferator-activated receptors (PPARs):nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflammation Research 49 10 2000 497 505
173. P. Delerive J.-C. Fruchart B. Staels Peroxisome proliferator-activated receptors in inflammation control. Journal of Endocrinology 169 3 2001 453 459
174. P. Henson hensonp@njc.org Suppression of macrophage inflammatory responses by PPARs. Proceedings of the National Academy of Sciences of the United States of America 100 11 2003 6295 6296
175. B. Zahorska-Markiewicz J. Janowska M. Olszanecka-Glinianowicz A. Zurakowski Serum concentrations of TNF-α and soluble TNF-α receptors in obesity. International Journal of Obesity 24 11 2000 1392 1395
176. M. Olszanecka-Glinianowicz B. Zahorska-Markiewicz J. Janowska A. Zurakowski Serum concentrations of nitric oxide, tumor necrosis factor (TNF)-α and TNFsoluble receptors in women with overweight and obesity. Metabolism: Clinical and Experimental 53 10 2004 1268 1273
177. G. S. Hotamisligil N. S. Shargill B. M. Spiegelman Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259 5091 1993 87 91
178. J. M. Stephens J. Lee P. F. Pilch puch@med-biochm.bu.edu Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompaniedby a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediatedsignal transduction. Journal of Biological Chemistry 272 2 1997 971 976
179. G. Kroder B. Bossenmaier M. Kellerer Tumor necrosis factor-α- and hyperglycemia-induced insulin resistance:evidence for different mechanisms and different effects on insulin signaling. Journal of Clinical Investigation 97 6 1996 1471 1477
180. J. S. Yudkin j.yudkin@med.ucl.ac.uk M. Kumari S. E. Humphries V. Mohamed-Ali Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148 2 2000 209 214
181. M. Olszanecka-Glinianowicz magols@esculap.pl M. Banaś B. Zahorska-Markiewicz Is the polycystic ovary syndrome associated with chronic inflammation per se? European Journal of Obstetrics Gynecology and Reproductive Biology 133 2 2007 197 202
182. Y.-F. Zhang Y.-S. Yang J. Hong Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine 29 3 2006 419 423
183. P. O. Szapary L. T. Bloedon F. F. Samaha Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabeticpatients with metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 26 1 2006 182 188
184. F. F. Samaha rick.samaha@med.va.gov P. O. Szapary N. Iqbal Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patientswith low high-density lipoprotein cholesterol and metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 26 3 2006 624 630
185. K. Esposito M. Ciotola D. Carleo Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 29 5 2006 1071 1076
186. T.-D. Wang W.-J. Chen J.-W. Lin M.-F. Chen Y.-T. Lee ytlee@ha.mc.ntu.edu. tw Effects of Rosiglitazone on endothelial function, C-reactive protein, and componentsof the metabolic syndrome in nondiabetic patients with the metabolic syndrome. American Journal of Cardiology 93 3 2004 362 365
187. T.-D. Wang tdwang@ha.mc.ntu.edu.tw W.-J. Chen W.-C. Cheng J.-W. Lin M.-F. Chen Y.-T. Lee Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone tochanges in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patientswith the metabolic syndrome. American Journal of Cardiology 98 8 2006 1057 1062
188. I. Tarkun ilhantarkun@superonline.com B. Çetinarslan E. Türemen T. Şahin Z. Cantürk B. Komsuoǧlu Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial functionin non-obese young women with polycystic ovary syndrome. European Journal of Endocrinology 153 1 2005 115 121
189. K. Rautio J. S. Tapanainen juha.tapanainen@oulu.fi A. Ruokonen L. C. Morin-Papunen Rosiglitazone treatment alleviates inflammation and improves liver function in overweightwomen with polycystic ovary syndrome: a randomized placebo-controlled study. Fertility and Sterility 87 1 2007 202 206
190. P. Hellberg P. Thomsen P. O. Janson M. Brannstrom Leukocyte supplementation increases the luteinizing hormone-induced ovulation rate in the in vitro-perfused rat ovary. Biology of Reproduction 44 5 1991 791 797
191. M. Brannstrom G. Mayrhofer S. A. Robertson Localization of leukocyte subsets in the rat ovary during the periovulatory period. Biology of Reproduction 48 2 1993 277 286
192. K. H. Van der Hoek S. Maddocks C. M. Woodhouse N. Van Rooijen S. A. Robertson R. J. Norman rnorman@medicine.adelaide.edu.au Intrabursal injection of clodronate liposomes causes macrophage depletion and inhibits ovulation in the mouse ovary. Biology of Reproduction 62 4 2000 1059 1066
193. P. E. Cohen K. Nishimura L. Zhu J. W. Pollard pollard@aecom.yu.edu Macrophages: important accessory cells for reproductive function. Journal of Leukocyte Biology 66 5 1999 765 772
194. M. Brännström P. O. Janson The biochemistry of ovulation. Ovarian Endocrinology Blackwell Science Oxford, UK 1991 133 166
195. R. Takaya T. Fukaya H. Sasano T. Suzuki M. Tamura A. Yajima Macrophages in normal cycling human ovaries; immunohistochemical localization and characterization. Human Reproduction 12 7 1997 1508 1512
196. E. Y. Anteby A. Hurwitz O. Korach Human follicular nitric oxide pathway:relationship to follicular size, oestradiol concentrations and ovarian blood flow. Human Reproduction 11 9 1996 1947 1951
197. C. Battaglia M. Salvatori N. Maxia F. Petraglia F. Facchinetti A. Volpe Adjuvant L-arginine treatment for in-vitro fertilization in poor responder patients. Human Reproduction 14 7 1999 1690 1697
198. D. G. Lemay D. H. Hwang dhwang@whnrc.usda.gov Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics. Journal of Lipid Research 47 7 2006 1583 1587
199. Y.-S. Tsai N. Maeda nobuyo@med.unc.edu PPARγ: a critical determinant of body fat distribution in humans and mice. Trends in Cardiovascular Medicine 15 3 2005 81 85
200. M. Stumvoll michael.stumvoll@med.uni-tuebingen.de H. Häring The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes 51 8 2002 2341 2347
201. P. D. G. Miles pmiles@ucsd.edu Y. Barak W. He R. M. Evans J. M. Olefsky Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency. Journal of Clinical Investigation 105 3 2000 287 292
202. J. Masugi Y. Tamori tamori@med.kobe-u.ac.jp H. Mori T. Koike M. Kasuga Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisomeproliferator-activated receptor-γ 2 on thiazolidinedione-induced adipogenesis. Biochemical and Biophysical Research Communications 268 1 2000 178 182
203. H. J. Antoine M. Pall B. C. Trader Y.-D. I. Chen R. Azziz M. O. Goodarzi mark.goodarzi@cshs.org Genetic variants in peroxisome proliferator-activated receptor γ influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome. Fertility and Sterility 87 4 2007 862 869
204. M. Mitkov B. Pehlivanov blago1956@yahoo.com D. Terzieva Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. European Journal of Obstetrics Gynecology and Reproductive Biology 126 1 2006 93 98
205. N. A. Cataldo nixie54@yahoo.com F. Abbasi T. L. McLaughlin Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin- resistantwomen with polycystic ovary syndrome. Human Reproduction 21 1 2006 109 120
206. A. Lemay andre.lemay@ogy.ulaval.ca S. Dodin L. Turcot F. Déchêne J.-C. Forest Rosiglitazone and ethinyl estradiol/ cyproterone acetate as single and combined treatmentof overweight women with polycystic ovary syndrome and insulin resistance. Human Reproduction 21 1 2006 121 128
207. R. V. Mehta K. S. Patel M. S. Coffler Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovarysyndrome despite improved insulin sensitivity during pioglitazone treatment. Journal of Clinical Endocrinology and Metabolism 90 4 2005 2136 2141